Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 6/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6372620 | 1.00 | SERPINE1 (1.00) | SERPINE1TRPA1HRH3RAF1CYP1A2 | |
| SCHEMBL6373495 | 0.86 | SERPINE1 (0.76) | SERPINE1CYP1A2METAP1MAPT | |
| SCHEMBL6373498 | 0.86 | SERPINE1 (0.76) | SERPINE1CYP1A2METAP1MAPT | |
| SCHEMBL6379183 | 0.85 | SERPINE1 (0.74) | SERPINE1METAP1MAPTPIM1AKR1B1 | |
| SCHEMBL6379176 | 0.85 | SERPINE1 (0.74) | SERPINE1METAP1MAPTPIM1AKR1B1 | |
| SCHEMBL6373541 | 0.84 | SERPINE1 (0.72) | SERPINE1HRH3METAP1MAPTPIM1 | |
| SCHEMBL6373545 | 0.84 | SERPINE1 (0.72) | SERPINE1HRH3METAP1MAPTPIM1 | |
| SCHEMBL6380159 | 0.84 | SERPINE1 (0.70) | SERPINE1HRH3RAF1CYP1A2CDK1 | |
| SCHEMBL6373509 | 0.84 | SERPINE1 (0.70) | SERPINE1HRH3RAF1CYP1A2CDK1 | |
| SCHEMBL6373505 | 0.84 | SERPINE1 (0.70) | SERPINE1HRH3RAF1CYP1A2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | THE UNIVERSITY OF CHICAGO (US) | 2025-08-12 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240382452-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX INC (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2023086343-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20050249681-A1 | Use of diketopiperazine derivatives as photostable uv-filters in cosmetic and pharmaceutical preparations | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-10 | — | — | US | disclosed |
| US-5902812-A | Pharmaceutical piperazine compounds | XENOVA LIMITED (GB) | 1999-05-11 | — | — | US | disclosed |
| US-5861400-A | TREATING RESISTANCE TO AN ANTHRACYLCINE ANTIBIOTIC WITH ADIKETOPIPERAZINE COMPOUND | XENOVA LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| US-5852018-A | Pharmaceutical piperazine compounds | XENOVA LIMITED (GB) | 1998-12-22 | — | — | US | disclosed |
| EP-0655060-B1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LTD (GB) | 1998-01-14 | — | — | EP | disclosed |
| US-5700804-A | INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITORS | XENOVA LIMITED (GB) | 1997-12-23 | — | — | US | disclosed |
| EP-0672036-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995021830-A1 | PHARMACEUTICAL PIPERAZIN COMPOUNDS | XENOVA LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995021831-A1 | PHARMACEUTICAL PIPERAZINE COMPOUNDS | XENOVA LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995021829-A1 | PHARMACEUTICAL PIPERAZINE COMPOUNDS | XENOVA LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
| EP-0655060-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994004512-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994004513-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | SERPINE1 53/4885TRPA1 1374/4885HRH3 271/4885 |
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | PLAT, PLG, SERPINB10 | SERPINE1 4/4885TRPA1 4602/4885HRH3 627/4885 |
| US-20050249681-A1 | Use of diketopiperazine derivatives as photostable uv-filters in cosmetic and pharmaceutical preparations | DHPS, MC1R, MITF | SERPINE1 1257/4885TRPA1 338/4885HRH3 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.